Background
High blood pressure (BP) is a controllable risk factor in the development of cardiovascular conditions, and therefore any food component with the ability to reduce BP could contribute to the prevention or treatment of cardiovascular diseases [
1‐
3].
Milk-derived peptides have been identified as potential antihypertensive agents. The best-characterized peptides found in fermented or enzymatically treated milk are Isoleucine-Proline-Proline (IPP), and Valine-Proline-Proline (VPP). Over twenty five human studies have been performed linking the consumption of products containing both IPP and VPP with significant reductions in BP [
4‐
6]. Fifteen of the BP studies have been done in Japanese subjects. Ten studies have been performed in Caucasians, that is, in Finnish subjects [
7‐
10], Dutch subjects [
11‐
14], Scottish subjects [
15] and American subjects [
16].
Effective dosages range from 3.07 mg/d (1.60 mg IPP and 1.47 mg VPP) to 52.5 mg/d (30 mg IPP and 22.5 mg VPP) [
10,
17]. Recently, casein hydrolysates with different bioactive peptide profiles were developed based on their in vitro ACE inhibitory potential: MPH1 (or tensVida™) and MPH2. The identified peptide contributing to ACE inhibitory effects in MPH1 is IPP, and those in MPH2 are Methionine-Alanine-Proline (MAP), IPP, and Leucine-Proline-Proline (LPP). In the ACE inhibition assays, MPH2 was somewhat more potent than MPH1.
An advantage is that these products contain a negligible amount of minerals contrasting with all other lactotripeptide-based products tested so far [
18‐
23]. Although the dosages of minerals in the sour milk are much lower than those that were effective in lowering BP in intervention trials, and placebo treatments were controlled for mineral content, it is possible that the minerals may have induced additive or synergistic BP effects. To our knowledge, this is the first study performed in Caucasian subjects using products with a negligible amount of minerals.
The primary objective of the study was to investigate the effectiveness of MPHs on reducing BP as well as to investigate safety parameters and tolerability in subjects with prehypertension and stage 1 hypertension. The secondary objective was to obtain information on the mechanism of action underlying the BP effects. The dose chosen is somewhat higher than the lower doses tested for similar products earlier in Japanese subjects, in view of the fact that Caucasian subjects tend to show a smaller blood pressure lowering toward lactotripeptide treatment than Japanese [
5,
6].
Methods
Study participants
Male and female Caucasian subjects were recruited from the pool of volunteers of TNO Quality of Life. After being informed about the study, the subjects gave voluntary written informed consent. Health was assessed by an interview on medical history, physical examination, and routine laboratory tests on blood and urine. To select subjects with prehypertension and stage 1 hypertension, the classification according to JNC-7 was used [
24]: subjects with a systolic BP between 140 - 159 mm Hg or a diastolic BP between 90 - 99 mm Hg were assigned to 'stage 1 hypertension', and subjects with a systolic BP between 120 - 139 mm Hg or a diastolic BP between 80 - 89 mm Hg were designated 'prehypertension'. BP was measured on three separate visits. Subjects with a history of medical events or medication that may have influenced the study outcome were excluded from participation. Subjects who were on slimming, medically prescribed, vegan, vegetarian or macrobiotic diet were also excluded as were smokers and subjects using more than 28 units (men) or 21 units (women) of alcohol per week to exclude alcoholics. Pregnant or lactating women were also excluded from participation. Eighty healthy subjects were included in the study.
Study design
The study was designed as a randomized, placebo-controlled, double blind, crossover study. Study treatments were given to the subjects according to a Latin square design. In view of the very short half-life of lactotripeptides [
25], no wash-out period was included between treatments. The study was powered to detect a 3.5 mmHg systolic blood pressure difference between placebo and treatment at an α of 0.05 (two-sided) and a β of 0.8.
Study protocol
Subjects visited the test facility of TNO Quality of Life at three consecutive test days at the end of each treatment period. At the first two test days, BP measurements were performed two hours after the subjects had their own habitual breakfast and the study substances at home. At the third test day, subjects came in a fasted state for collection of blood and spot-urine samples. No alcohol and sports were allowed the day before the test days, and no dairy products were allowed at breakfast on the test days. During the study period, subjects were instructed not to consume more than one portion of a fermented dairy product per day.
The study was performed according to the ICH Guideline for Good Clinical Practice (ICH topic E6, adopted 01-05-1996 and implemented 17-01-1997) and was approved by the independent Medical Ethics Committee METOPP (Tilburg, the Netherlands).
Study products
MPH1 and MPH2 were produced through hydrolysis of glycomacropeptide and casein, respectively. Hydrolysis was performed using a proline-specific endoprotease. The nutritional properties, as well as the amounts of bioactive peptides of the study products are presented in table
1. Lactotripeptides were quantified as described in [
26].
Table 1
Characteristics of study products
Protein | 570.0 | 570.0 | - |
Fat | 2.5 | 2.3 | - |
Carbohydrates | 3.4 | 13.7 | 570 |
Na | 3.1 | 0.9 | - |
Ca | 5.9 | 1.0 | - |
K | 2.5 | 34.3 | - |
Fibre | - | - | 570 |
Ashes (%) | 8 | 5 | nd |
Total Organic Solids (%) | 89 | 75 | nd |
IPP | 7.5 | 1.8 | - |
MAP | - | 6.6 | - |
LPP | - | 2.3 | - |
Study treatments
Study treatments were offered to the volunteers in capsules, to exclude any pre-ingestion interference with food matrices. The treatments consisted of consumption of MPH1 or MPH2 or placebo during 4 weeks. Five hundred mg hydrolysed protein was used per capsule for each of the MPH treatments. The lactotripeptide content per capsule was 7.5 mg IPP for MPH1, and 6.6 mg MAP, 2.3 mg LPP, and 1.8 mg IPP for MPH2. Subjects received 2 capsules per day, and were instructed to consume one capsule directly upon completion of breakfast and one capsule directly upon completion of dinner. Placebo treatment consisted of daily consumption of 2 capsules, each of them filled with 500 mg cellulose (food grade quality).
Blood pressure measurements
BP was measured between 2.5 and 3.5 h after ingestion of the study substances using automated digital sphygmomanometry (OMRON IC). In brief, subjects rested for at least 15 min at room temperature. The BP cuff was placed around the upper left arm which was supported at the level of the heart while the subject sat in a chair with the feet positioned flat on the floor and with a straight back rested against the chair. The first measurement was taken after three minutes rest. The subject was told not to move or speak. In total four measurements were taken with one minute rest in between. The average of the last three measurements was calculated.
Safety parameters
Clinical laboratory tests were performed at screening and at the end of treatment and included hematology, serum chemistry (liver enzymes, albumin, bilirubin, urea, creatinin, cholesterol parameters, triacylglycerols, glucose, minerals, blood sedimentation rate, and C-reactive protein). Blood samples were obtained from the antecubital vein of the forearm and collected in tubes containing clot activator for serum and in tubes containing potassium ethylene diamine tetra acid (K3EDTA) for plasma (Vacutainer Systems, Becton Dickinson, Plymouth, UK). Blood was centrifuged for 15 min at ca. 2,000 × g at ca. 4°C within 15-30 min after collection, and stored at -20°C until analysis. All biochemical determinations in blood were performed at TNO Quality of Life using Olympus AU400 analytical equipment and reagents. Dipstick urinalysis was performed on the day of collection to assess the presence of protein, glucose, leucocytes, erythrocytes, nitrite, pH, ketones, bilirubin, and urobilinogen. A microscopic inspection of sediment was done if the dipstick test gave values above the normal range for leucocytes, blood or protein.
At the end of treatment, subjects indicated the presence or absence of a number of possible adverse effects in a questionnaire using a 4-point scale from 'not at all' to 'very often'. Symptoms included not feeling well, headache, weakness, fatigue, nausea, vomiting, burping, stomach-ache, bloating, flatulence, constipation, diarrhea, dry mouth, change of taste, cough, and skin complaints.
Mechanistic parameters
For renin, blood was collected in Vacutainer® tubes containing K3EDTA as anticoagulant and centrifuged immediately (15 minutes at 2,000 × g and ca. 20°C). Plasma was snap frozen in liquid nitrogen and stored at -80°C. For angiotensin I and II, blood was collected in Vacutainer® tubes containing K3EDTA as anticoagulant and protease inhibitor buffer was added at an amount of 50 μL buffer/ml blood. The buffer consisted of (stock 100 mL): 4250 mg EDTA, 8.13 mg enalaprilate, 200 mg neomycin, 0.5 mg o-phenantroline, 2% ethanol, 6 mg renin inhibitor (Sigma, cat.nr. C9415). Samples were centrifuged within 10 minutes after collection (15 minutes at 2,000 × g at 4°C) and plasma was snap frozen in liquid nitrogen and stored at -80°C.
Renin was measured by a standard immunoradiometric assay (Schering SA, CIS bio international, France). Intra- and inter-assay coefficients of variation were 4.1% and 7.6%, respectively. Angiotensin I and II were measured by a standard radioimmunoassay (Peninsula Laboratories, St. Helens, UK) following C-18 Sep-Pak (Waters-Millipore) extraction of the peptide. Intra- and inter-assay coefficients of variation were 4.6% and 7.7%, respectively.
Statistical analysis
For blood pressure, for every subject and treatment, measurements were first averaged per test day, and subsequently averaged over two successive test days. Statistical analysis of treatment effects on mean DBP and SBP and on mechanistic parameters was performed taking into account the study population, BP class (i.e. prehypertension or stage 1 hypertension), treatment, and interaction between treatment and BP class. Treatment effects were investigated using 2-way ANOVA. Carry over analysis was performed to determine whether a carry over correction was necessary. In case no significant carry over effect was found, the model was simplified by removing this effect. If the analysis of variance indicated an overall treatment effect (P < 0.05), comparisons between treatment means were performed using a 2-sided (paired) Student's t-test. Dichotomized scores in the questionnaire on possible adverse-effects were analyzed using Cochran-Mantel-Haenszel statistics taking into account multiple measurements per subject. In all statistical tests, the null hypothesis was rejected at the 0.05 level of probability (α = 5%). All data are presented as mean ± standard deviation (SD). Statistical analysis of the data was carried out using the SAS statistical software package (SAS/STAT Version 8.2, SAS Institute, Cary, NC).
Discussion
In subjects with stage 1 hypertension, daily intake of MPH1, delivering 15 mg IPP, for 4 weeks lowered systolic BP by 3.8 mm Hg and diastolic BP by 2.3 mm Hg compared with placebo. Daily intake of MPH2 containing 13.2 mg MAP, 4.6 mg LPP, and 3.7 mg IPP did not affect BP in these subjects. Since MPH1 contains primarily IPP while MPH2 contains mainly MAP and LPP, this differential effect despite equal protein dose of the two treatments suggests superiority of IPP over the other peptides for BP lowering, or even functional antagonism of MAP and LPP against IPP (i.e. MAP and LPP having an opposite effect compared to IPP in vivo). Alternatively, MAP and LPP may be less bioavailable than IPP. The bioavailability of IPP has been demonstrated in humans [
25], but bioavailability data for MAP and LPP are lacking.
In our study MPHs were given for a period of 4 weeks. A further lowering of BP might have been achieved in a longer treatment periods as has been shown in studies on comparable products [
27‐
30].
In subjects with prehypertension, daily intake of both MPH1 and MPH2 did not affect BP. Also in other studies, lactotripeptides, in particular VPP and IPP, appear more effective in reducing BP of subjects with a higher starting BP (Sano et al, 2005; Aihara et al, 2005). Indeed, in none of the trials with normotensives were any statistically significant BP changes found [
31‐
34]. This is in line with findings in studies using pharmaceutical interventions [
35].
In many papers, BP reduction through lactotripeptides has been suggested to be due to inhibition of the renin-angiotensin system, which plays an important role in regulating arterial pressure. Renin converts angiotensinogen to the biologically inactive angiotensin I, which in turn undergoes proteolytic cleavage by ACE to the vasoconstrictor angiotensin II [
36]. Inhibition of ACE leads to an increase of the angiotensin I/angiotensin II ratio and a subsequent compensatory increase in renin activity. We could not demonstrate any effects of either MPH on renin activity, angiotensin I and II. Although local ACE inhibitory effects near the vascular wall may be overlooked by measuring angiotensin in blood samples from the systemic circulation, these findings do not support an angiotensin-mediated effect of ACE inhibition in vivo. This may explain why the in vitro ACE inhibitory potency of MPH1 and MPH2 did not predict their BP lowering activity. Indeed, based on their IC50 values, MPH2 was expected to lower BP more than MPH1, but the contrary was found in this study.
An alternative way in which ACE inhibition could be involved in the observed BP effects would be through an increased availability of the endogenous vasodilator bradykinin [
37]. Alternative mechanisms, such as such as opioid-like activities, inhibition of the release of the vasoactive substances such as the vasoconstrictor endothelin-1, eicosanoids and nitric oxide have been proposed to underlie the blood pressure lowering effect of lactotripeptides (see [
38] for a review). Further work is needed to better characterize these mechanisms.
Since lactotripeptides are frequently taken in a dairy drink or a similar vehicle, it is often unclear whether the blood pressure lowering effects are solely due to the lactotripeptides, or whether minerals in these drinks contribute to the blood pressure lowering effects as well. In the current study, the lactotripeptides have been administered in capsules rather than in dairy drinks. Also, MPH1 contains very few minerals (1.1 mg K
+ + Ca
2+ per mg IPP) compared to other products that have been administered in capsules in other studies (2.3 - 3.6 mg K
+ + Ca
2+ per mg IPP) [
28,
31,
33,
39]. Therefore, it is very unlikely that minerals have contributed to the observed blood pressure lowering effect.
The doses of MPH used in this study did not exert any significant effects on blood and urine parameters, adverse events, and other adverse effects, and were thus considered safe. Previous studies confirmed that even high daily dosages of VPP and IPP were safe [
10,
31,
33,
34,
39].
The BP reductions found for MPH1 are in the order of magnitude of those that can be achieved by lifestyle modifications, such as weight loss in overweight subjects [
40], regular aerobic exercise [
41,
42], adjustment of dietary habits [
43], and moderation of alcohol consumption [
44]. Cook and co-workers [
45] and Whelton and co-workers [
41] investigated the impact of small reductions in the population distribution of diastolic BP, such as those found in our study and those potentially achieved by lifestyle modification, on incidence of cardiovascular heart disease and stroke. Cook estimated that a 2 mm Hg reduction in the population average of diastolic BP for white US subjects aged 35-64 y would result in a 17% decrease in the prevalence of hypertension, a 15% reduction in the risk of stroke, and a 6% reduction in the risk of coronary heart disease.
Competing interests
E.B. did not have a conflict of interest. J.K. is employed as a senior scientist at the Department of Nutrition and Health at DSM Biotechnology Center, the Netherlands.
The study was financially supported by DSM Food Specialties, Delft, the Netherlands, the manufacturer of the study substances.
Authors' contributions
EB and JK were responsible for design of the study; EB was responsible for conduct of the study and data interpretation; EB and JK wrote the manuscript; Both JK and EB read and approved the final version.